Background: Malignant melanoma is a cancer that demonstrates rapid progression and atypical clinicallyfeatures with a poor prognosis. Aim: This study was performed to determine the clinical characteristics andtreatment outcomes of patients with malignant melanoma in Turkey. Methods: The medical records of 98patients between 2007- 2012 at our centers were retrieved from the patient registry. Overall survival (OS) wascalculated using the Kaplan-Meier method. Results: In our study, with the median follow-up of all patientswith cutaneous MM of 46.3 months, the median OS rate of all cases was 43.6 months and 5-year OS was 48.6%.However, five-year OS rates of patients with localized disease (stage I-II) and node involvement (stage III) were60.3% and 39.6%, respectively. The median OS of stage IV patients was 8.7 months and 1-year OS rate was26.2%. We showed that advanced stage, male gender, and advanced age in all patients with MM were significantprognostic factors of OS. Conclusions: Compared with the results of current studies from Western countries,we found similar findings concerning demographical features, histological variables and survival analyses forour patients with cutaneous MM in Turkey.
(2013). Multicenter Evaluation of Patients with Cutaneous Malignant Melanoma in Turkey: MELAS Study. Asian Pacific Journal of Cancer Prevention, 14(1), 533-537.
MLA
. "Multicenter Evaluation of Patients with Cutaneous Malignant Melanoma in Turkey: MELAS Study". Asian Pacific Journal of Cancer Prevention, 14, 1, 2013, 533-537.
HARVARD
(2013). 'Multicenter Evaluation of Patients with Cutaneous Malignant Melanoma in Turkey: MELAS Study', Asian Pacific Journal of Cancer Prevention, 14(1), pp. 533-537.
VANCOUVER
Multicenter Evaluation of Patients with Cutaneous Malignant Melanoma in Turkey: MELAS Study. Asian Pacific Journal of Cancer Prevention, 2013; 14(1): 533-537.